About Gufic Biosciences Limited

Gufic Biosciences Limited (Gufic) is a Mumbai-headquartered pharmaceutical company incorporated on July 23, 1984, and listed on both BSE (Scrip Code: 509079) and NSE (Symbol: GUFICBIO). Founded by Late Shri Pannalal S. Choksi, Gufic has grown into a leading global pharmaceutical manufacturer, offering end-to-end healthcare solutions backed by a strong R&D foundation, extensive product range, and robust distribution network. It consistently ranks among the top 100 pharmaceutical companies in India.

A pioneer in lyophilised (freeze-dried) injections, the Company operates state-of-the-art automated lyophilisation facilities at Navsari (Gujarat) and Indore (Madhya Pradesh). Its diversified portfolio spans herbal formulations, antibiotics, antifungals, cardiology, infertility, antivirals, and Proton Pump Inhibitors (PPIs). Pharmaceutical manufacturing and marketing account for 100% of turnover.

Gufic’s geographic reach is extensive — it serves 28 States and 8 Union Territories within India and exports to 70+ countries across multiple continents. The Company has three manufacturing plants, 22 offices (including Carrying & Forwarding Agent locations) in India, and two international offices. Gufic’s international footprint continues to expand in Germany, Switzerland, South Africa, Russia, Canada, Brazil, Europe, and other emerging markets.

As of March 31, 2025, Gufic has three subsidiaries, which did not undertake business operations during the financial year. The Company was recognised as one of the “Most Preferred Workplaces for Women” for FY 2024–25 (September 2024, Mumbai), underlining its commitment to inclusive and progressive workplace practices.

Business Segments

• Segment/Vertical: Pharmaceutical Manufacturing and Marketing – 100% of turnover
• Domestic vs International (FY 2024–25):
  • Domestic: 79.83%
  • Exports: 20.17% (vs 10.93% in the previous year)

Gufic Biosciences Limited Key Management

• Mr. Jayesh P. Choksi – Chairman & Managing Director
• Mr. Pranav J. Choksi – Chief Executive Officer & Whole-Time Director
• Mr. Pankaj J. Gandhi – Whole-Time Director
• Mr. Devkinandan B. Roonghta – Chief Financial Officer
• Ms. Ami N. Shah – Company Secretary & Compliance Officer
• Mr. Nagesh Yarrabathina – Chief Operating Officer

Latest Updates on Gufic Biosciences Limited

• Portfolio Expansion:
  Gufic launched 10 new generic products during FY 2024–25, with 10 more ready for commercialisation and 50+ products in various stages of development.
• Innovation & Intellectual Property:
  The Company filed patents for complex and novel dosage forms, including an aqueous-based Vitamin D3 injection and other life-saving injectables. All R&D is supported by in-house quality assurance and stability testing, enhancing bioavailability and reliability.
• Strategic Collaborations:
  Gufic strengthened collaborations with independent R&D teams to introduce new products and technologies and expanded its presence in regulated markets using its domestic product pipeline.
• Manufacturing Leadership:
  The Company reaffirmed its position as a global leader in lyophilised injectables through its automated facilities in Navsari and Indore, which are benchmarked to global quality standards.
• Market Reach:
  As of March 31, 2025, exports contributed 20.17% of turnover, up from 10.93% the previous year — reflecting growing international traction. Domestically, the Company continues to serve 28 States and 8 Union Territories, with exports to 70+ countries.

Workplace Recognition:
Awarded “Most Preferred Workplace for Women” for FY 2024–25, recognising Gufic’s employee-centric culture, gender inclusivity, and strong governance.

Note: All information is sourced exclusively from Gufic Biosciences Limited’s Annual Report for FY 2024–25, including the Directors’ Report, Management Discussion & Analysis, Financial Statements, and Statutory Disclosures.